Sterically hindered phenanthroimidazole ligands drive the structural flexibility and facile ligand exchange in cyclometalated iridium(III) complexes

Design and anticancer behaviour of cationic/neutral half-sandwich iridium(III) imidazole-phenanthroline/phenanthrene complexes

Considerable attention has been devoted to the exploration of organometallic iridium(III) (IrIII) complexes for their potential as metallic anticancer drugs. In this study, twelve half-sandwich IrIII imidazole-phenanthroline/phenanthrene complexes were prepared and characterized. Complexes exhibited promising in-vitro anti-proliferative activity, and some are obviously superior to cisplatin towards A549 cells. These complexes possessed suitable fluorescence, and a non-energy-dependent uptake pathway was identified, subsequently leading to their accumulation in the lysosome and the lysosomal damage. Additionally, complexes could inhibit the cell cycle (G1-phase) and catalyze intracellular NADH oxidation, thus substantiating the elevation of intracellular reactive oxygen species (ROS) level, which confirming the oxidative mechanism. Western blotting further confirmed that complexes could induce A549 cell apoptosis through the lysosomal-mitochondrial anticancer pathway, which was inconsistent with cisplatin. In summary, these complexes offer fresh concepts for the development of organometallic non‑platinum anticancer drugs.

Neutral 2-phenylbenzimidazole-based iridium(III) complexes with picolinate ancillary ligand: tuning the emission properties by manipulating the substituent on the benzimidazole ring

We report the synthesis and characterization of ten neutral bisheteroleptic iridium(III) complexes with 2-phenylbenzimidazole cyclometallating ligand and picolinate as ancillary ligand. The 2-phenylbenzimidazole has been modified by selected substituents introduced on the cyclometallating ring and/or on the benzimidazole moiety. The integrity of the complexes has been assessed by NMR spectroscopy, by high-resolution mass spectrometry and by elemental analysis. The complexes are demonstrated to be highly phosphorescent at room temperature and a luminescence study with comprehensive ab initio calculations allow us to determine the lowest emitting excited state which depends on the substituent nature and its position on the cyclometallating ligand.

Recent Advances in Organometallic NIR Iridium(III) Complexes for Detection and Therapy

Iridium(III) complexes are emerging as a promising tool in the area of detection and therapy due to their prominent photophysical properties, including higher photostability, tunable phosphorescence emission, long-lasting phosphorescence, and high quantum yields. In recent years, much effort has been devoted to develop novel near-infrared (NIR) iridium(III) complexes to improve signal-to-noise ratio and enhance tissue penetration. In this review, we summarize different classes of organometallic NIR iridium(III) complexes for detection and therapy, including cyclometalated ligand-enabled NIR iridium(III) complexes and NIR-dye-conjugated iridium(III) complexes. Moreover, the prospects and challenges for organometallic NIR iridium(III) complexes for targeted detection and therapy are discussed.

Aggregation-induced emission of cyclometalated rhodium(III) and iridium(III) phenylpyridine complexes with ancillary 1,3-diketones

A joint structural and spectroscopic study of simple bis-cyclometataled rhodium(III) and iridium(III) complexes with 2-phenylpyridine and aromatic β-diketones (dibenzoylmethane, benzoylacetone, benzoyltrifluoroacetone, and 2-thenoyltrifluoroacetone) reveals an interplay between the solid-state emission efficiency and crystal packing peculiarities of the complexes. Although the prepared rhodium(III) cyclometalates are isostructural with iridium(III) analogues, different types of π-π interactions are responsible for the aggregation-induced emission (AIE) of the complexes depending on the metal ion. For iridium(III) complexes, pyridyl-pyridyl contacts are essential for AIE because they lower the energy of the emissive metal-to-ligand charge transfer state below that of the non-emissive state located at the ancillary ligand. Enabled by phenyl-pyridyl interactions partially blocking the population of non-emissive d-d states, solid-state phosphorescence enhancement is successfully achieved in a rhodium(III) complex with ancillary benzoyltrifluoroacetone, which is the first example of a rhodium complex exhibiting AIE.

Rational design of efficient photosensitizers based on cyclometalated iridium(III) complexes with 2-arylbenzimidazole and aromatic 1,3-diketone ligands

A judicious selection of substituents in cyclometalating 2-arylbenzimidazoles and an ancillary aromatic 1,3-diketone enabled the creation of heteroleptic iridium(III) complexes demonstrating strong light absorption up to 500 nm (ε ≈ 10 000-12 000 M-1 cm-1). The complexes, which were studied by various spectroscopic techniques, single-crystal X-ray diffraction and cyclic voltammetry, displayed tunable absorption maxima depending on the nature of substituents and their positions. The experimental study was corroborated by quantum chemical calculations, which showed an increased contribution of intraligand charge transfer transitions to the visible light absorption in the case of complexes containing electron-withdrawing substituents in the ligands. Despite being of high intensity, some of these transitions are responsible for the formation of the excited states located at large distances from the 'anchoring' fragment incorporated in the ancillary ligand. In turn, incorporation of electron-donating substituents at the para-position to the Ir-C bonds increases the number of excited states located on the ancillary ligand. The destabilization of the HOMO, which is caused by the increase in the electron-donating ability of the substituents in the metalated rings, translated into negative shifts of the Ir4+/Ir3+ redox potential, affecting, in some cases, the degree of electrochemical reversibility of the complexes. Several complexes having strong light-harvesting characteristics and undergoing reversible oxidation in the appropriate potential range were used for coating the TiO2 photoanodes, which reached an efficiency of 2.15% upon irradiation with the standard AM 1.5 spectrum.

Fine-Tuning of the Optical and Electrochemical Properties of Ruthenium(II) Complexes with 2-Arylbenzimidazoles and 4,4'-Dimethoxycarbonyl-2,2'-bipyridine

A series of cyclometalated complexes of ruthenium (II) with four different substituents in the aryl fragment of benzimidazole was synthesized in order to study the effect of substituent donation on the electronic structure of the substances. The resulting complexes were studied using X-ray diffraction, NMR spectroscopy, MALDI mass spectrometry, electron absorption spectroscopy, luminescence spectroscopy, and cyclic voltammetry as well as DFT/TDDFT was also used to interpret the results. All the complexes have intense absorption in the range of up to 700 nm, the triplet nature of the excited state was confirmed by measurement of luminescence decay. With an increase in substituent donation, a red shift of the absorption and emission bands occurs, and the lifetime of the excited state and the redox potential of the complex decrease. The combination of these properties shows that the complexes are excellent dyes and can be used as photosensitizers.

Tailoring the π-system of benzimidazole ligands towards stable light-harvesting cyclometalated iridium(III) complexes

The synthesis, structure, optical and redox properties as well as photovoltaic studies of iridium(III) complexes with cyclometalated 2-arylbenzimidazoles decorated with various polyaromatic fragments and an ancillary aromatic β-diketone are reported. Despite the strong preference of the iridium(III) ion to form bis- or tris-cyclometalated complexes in which the metal participates in five-membered metallacycles, the cyclometalation of the benzimidazole ligands containing rigid π-extended systems yields dimeric complexes containing strained five- or six-membered metallacycles and allows for generating an extremely rare monocyclometalated complex. X-ray crystallography shows that the steric strain observed in the dimers is retained in heteroleptic diketonate complexes which is also corroborated by gas-phase DFT calculations. While emission maxima and redox potentials of the heteroleptic complexes exhibit just a moderate variation upon the change of the cyclometalated ligands, the extension of the π-system of the benzimidazole ligands give the complexes remarkable light absorption in the visible spectral range, which meets the requirements for application in dye-sensitized solar cells. At the titania photoanodes, these iridium dyes retain their optical properties and exhibit power conversion efficiencies under standard AM 1.5 G conditions comparable to those of other iridium-based sensitizers. These results demonstrate that the size and position of the π-extended fragment in cyclometalated ligands can modulate not only the electronic structure of the corresponding iridium(III) complexes, but also affect their composition, structure and reactivity that may find implications in future design of emerging iridium dyes, emitters and catalysts.

A Panchromatic Cyclometalated Iridium Dye Based on 2-Thienyl-Perimidine

Though 2-arylperimidines have never been used in iridium(III) chemistry, the present study on structural, electronic and optical properties of N-unsubstituted and N-methylated 2-(2-thienyl)perimidines, supported by DFT/TDDFT calculations, has shown that these ligands are promising candidates for construction of light-harvesting iridium(III) complexes. In contrast to N-H perimidine, the N-methylated ligand gave the expected cyclometalated μ-chloro-bridged iridium(III) dimer which was readily converted to a cationic heteroleptic complex with 4,4′-dicarboxy-2,2′-bipyridine. The resulting iridium(III) dye exhibited panchromatic absorption up to 1000 nm and was tested in a dye-sensitized solar cell.

Bis-Heteroleptic Cationic Iridium(III) Complexes Featuring Cyclometalating 2-Phenylbenzimidazole Ligands: A Combined Experimental and Theoretical Study

In this report, we investigate a new family of cationic iridium(III) complexes featuring the cyclometalating ligand 2-phenylbenzimidazole and ancillary ligand 4,4'-dimethyl-2,2'-bipyridine. Our benchmark complex IrL¹₂ (L¹ = 2-phenylbenzimidazole) displays emission properties similar to those of the archetypical complex 2,2'-dipyridylbis(2',4'-phenylpyridine)iridium(III) in deaerated CH₃CN (Φ = 0.20, λ_em = 584 nm and Φ = 0.14, λ_em = 585 nm, respectively) but exhibits a higher photoluminescence quantum yield in deaerated CH₂Cl₂ (Φ = 0.32, λ_em = 566 nm and Φ = 0.20, λ_em = 595 nm, respectively) and especially a lower nonradiative constant (k_nr = 6.6 × 10⁵ s^-1 vs k_nr = 1.4 × 10⁶ s^-1, respectively). As a primary investigation, we explored the influence of the introduction of electron-donating and electron-withdrawing groups on the benzimidazole moiety and the synergetic effect of the substitution of the cyclometalating phenyl moiety at the para position with the same substituents. The emission energy displays very good correlation with the Hammett constants of the introduced substituents as well as with ΔE_redox values, which allow us to ascribe the phosphorescence of these series to emanate mainly from a mixed metal/ligand to ligand charge transfer triplet excited state (³M/LLCT*). Two complexes (IrL⁵₂ and IrL⁸₂) display a switch of the lowest triplet excited state from ³M/LLCT* to ligand centered (³LC*), from the less polar CH₂Cl₂ to the more polar CH₃CN. The observed results are supported by (TD)-DFT computations considering the vibrational contributions to the electronic transitions. Chromaticity diagrams based on the maximum emission wavelength of the recorded and simulated phosphorescence spectra demonstrate the strong promise of our complexes as emitting materials, together with the very good agreement between experimental and theoretical results.

Inherently dinuclear iridium(III) meso architectures accessed by cyclometalation of calix[4]arene-based bis(aryltriazoles)

Conventional cyclometalation of calix[4]arene bis(aryltriazoles) with iridium(III) chloride hydrate leads to unique meso architectures in which the Ir₂Cl₂ core is cross-bound by two (C^N)₂ ligands, which allows further replacement of the chloride bridges with ancillary ligands while maintaining the dinuclear structures of the complexes having independent or coupled iridium pairs.